New business development director at Movetis
This article was originally published in Scrip
Movetis, a European speciality pharmaceutical company focused on gastrointestinal conditions with a high unmet medical need, has appointed Bjoern Peters as its new business development director. He joins from Intendis in Berlin, a daughter company of Bayer Healthcare, where for the past two years he was regional business director responsible for Asia-Pacific, North Europe, and the Middle East. He has also had several years' experience as business development manager in previous positions with Janssen-Cilag.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.